Cooley advised Repare Therapeutics on its $253 million initial public offering of 12,650,000 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Repare Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol “RPTX”, is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Partners Div Gupta, Ryan Sansom and Marc Recht led the Cooley team.